Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach
Unknown status
Lymphoma Trials Office
Phase 3
1995-03-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. It is not yet known whether chlorambucil is more effective than
observation in treating low-grade lymphoma of the stomach.
PURPOSE: Randomized phase III trial to compare the effectiveness of chlorambucil with that of
no further therapy following anti-Helicobacter therapy in treating patients with low-grade
lymphoma of the stomach.
Helicobacter Pylori Eradication With a New Sequential Treatment
Completed
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 3
2001-01-01
Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are
disappointing, and studies from several countries confirm this poor performance. The study
aimed to assess the eradication rate of a new sequential treatment regimen compared with
conventional triple therapy for the eradication of H. pylori infection.
Helicobacter Pylori Eradication With a New Sequential Treatment
Completed
St. Orsola Hospital
Phase 3
2001-01-01
Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are
disappointing, and studies from several countries confirm this poor performance. The study
aimed to assess the eradication rate of a new sequential treatment regimen compared with
conventional triple therapy for the eradication of H. pylori infection.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
